Table 1.
Patient, Disease and Transplant Characteristics
| Characteristic | N=95 | % |
|---|---|---|
| Age (median, range) | 34 | (19–66) |
| Female | 48 | 50.5% |
| Race | ||
| White | 84 | 88.4% |
| Black | 7 | 7.4% |
| Other | 4 | 4.2% |
| Hodgkin Lymphoma Histology | ||
| Nodular Sclerosis | 66 | 69.5% |
| Mixed cellularity | 19 | 20.0% |
| Classical NOS | 1 | 1.1% |
| Lymphocyte Predominant | 4 | 4.2% |
| Lymphocyte Depleted | 3 | 3.2% |
| Unknown | 2 | 2.1% |
| Disease Stage at Diagnosis | ||
| Early Stage (I/II) | 43 | 45.3% |
| Advanced Stage (III/IV) | 50 | 52.6% |
| B symptoms at Diagnosis | 59 | 62.1% |
| Disease Status at Transplant | ||
| First Relapse | 57 | 60.0% |
| Primary Refractory or Induction Failure | 33 | 34.7% |
| Advanced Disease | 5 | 5.3% |
| Chemosensitivity | ||
| Chemosensitive | 74 | 77.9% |
| Conditioning Regimen | ||
| BEAC | 50 | 52.6% |
| BEAM | 36 | 37.9% |
| TBI+cyclophosphamide | 9 | 9.5% |
| Consolidative Radiation Therapy | 47 | 49.5% |
| Graft Type | ||
| Bone Marrow | 17 | 17.9% |
| Peripheral Blood | 66 | 69.5% |
| Bone Marrow + Peripheral Blood | 12 | 12.6% |
HL, Hodgkin Lymphoma; HD-ASCT, high-dose autologous stem cell transplant